Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from the research support business was ¥947 million, up 6.7% year on year, while revenue from the medical business was ¥209 million, up 141.6%. No specific direct factors behind the increase or decrease were identified.
There were no applicable notes regarding the going concern assumption. However, the Company states that events or conditions exist that raise significant doubt about the going concern assumption, as research and clinical trial expenses continue to precede revenue and operating losses continue to be incurred. It presents its financial base, including cash and deposits and securities, and states that it aims to return to profitability at an early stage through sales promotion and cost controls.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥1,156 million (YoY +18.7%) |
| Operating profit | ¥-497 million |
| Ordinary income | ¥-318 million |
| Profit attributable to owners of the parent | ¥-319 million |
| Net income per share | -¥3.24 |
| Equity ratio | End of the current fiscal period 90.6 / End of previous period 91.7 |
| Total assets | ¥11,338 million |
| Net assets | ¥10,288 million |
| Cash flows from operating activities | ¥-343 million |
| Cash flows from investing activities | ¥-531 million |
| Cash flows from financing activities | ¥1,100 million |
| Cash and cash equivalents at end of period | ¥2,815 million |
| Full-year earnings forecast | Net Sales ¥2,629 million (YoY +17.7%) / Operating profit ¥-630 million / Ordinary income ¥-458 million / Net income ¥-458 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Research Support Business ¥947 million (YoY +6.7%), Medical business ¥209 million (YoY +141.6%) |
| Segment profit | Research Support Business ¥70 million, Medical business ¥-23 million |
| Regional sales | ¥350,231 thousand, ¥480,460 thousand, ¥278,590 thousand, ¥46,909 thousand |
| Depreciation and amortization | ¥40,541 thousand |
| Impairment loss | None |
| Breakdown of extraordinary income (loss) | Not applicable |
| Disclosure regarding the going concern assumption | There were no applicable notes regarding the going concern assumption. However, the Company states that events or conditions exist that raise significant doubt about the going concern assumption, as research and clinical trial expenses continue to precede revenue and operating losses continue to be incurred. It presents its financial base, including cash and deposits and securities, and states that it aims to return to profitability at an early stage through sales promotion and cost controls. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | On 20 October 2026, the Company issued 2,932,000 common shares to CVI Investments, Inc. through a third-party allotment and completed payment. It also issued 29,320 20th series stock acquisition rights. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 103,943,891 |
| Treasury Shares at Period-End | 117,285 |
| Factors Behind Changes in Business Performance | Revenue from the research support business was ¥947 million, up 6.7% year on year, while revenue from the medical business was ¥209 million, up 141.6%. No specific direct factors behind the increase or decrease were identified. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from the research support business was ¥947 million, up 6.7% year on year, while revenue from the medical business was ¥209 million, up 141.6%. The Company describes the product and service rollout of each business, as well as research and development, contract manufacturing and clinical testing services, but does not identify specific direct factors behind the increase in revenue and the narrower loss for the interim period.